{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:28:16Z","timestamp":1789525696050,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004915","name":"Texas Commission on the Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017455","name":"Social Science Research Institute, Duke University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017455","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473376"],"award-info":[{"award-number":["81473376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730096"],"award-info":[{"award-number":["81730096"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773924"],"award-info":[{"award-number":["81773924"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130109"],"award-info":[{"award-number":["82130109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejphar.2022.175070","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T11:12:10Z","timestamp":1654081930000},"page":"175070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Comparative efficacy and acceptability of drug treatments for Parkinson\u2019s disease with depression: A systematic review with network meta-analysis"],"prefix":"10.1016","volume":"927","author":[{"given":"Xiao-Le","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Tong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7422-8206","authenticated-orcid":false,"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175070_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrneurol.2011.189","article-title":"Depression in Parkinson disease--epidemiology, mechanisms and management","volume":"8","author":"Aarsland","year":"2011","journal-title":"Nat. Rev. Neurol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2022.175070_bib2","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1002\/mds.870080508","article-title":"Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial","volume":"8","author":"Allain","year":"1993","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib47","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4088\/JCP.v64n0216","article-title":"A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder","volume":"64","author":"Amsterdam","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2022.175070_bib49","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/ene.12757","article-title":"Effects of rotigotine transdermal patch in patients with Parkinson\u2019s disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial","volume":"22","author":"Antonini","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib48","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/mds.20895","article-title":"Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson\u2019s disease and depression: effect on quality of life","volume":"21","author":"Antonini","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib3","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S1474-4422(16)30230-7","article-title":"The epidemiology of Parkinson's disease: risk factors and prevention","volume":"15","author":"Ascherio","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/01.jcp.0000088908.24613.db","article-title":"Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial","volume":"23","author":"Avila","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2022.175070_bib53","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mds.21191","article-title":"Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson\u2019s disease","volume":"22","author":"Barone","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib54","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejphar.2022.175070_bib4","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/ene.12724","article-title":"A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients","volume":"22","author":"Barone","year":"2015","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00415-006-0067-5","article-title":"Pramipexole versus sertraline in the treatment of depression in Parkinson\u2019s disease: a national multicenter parallel-group randomized study","volume":"253","author":"Barone","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.ejphar.2022.175070_bib52","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","article-title":"Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients","volume":"159","author":"Bodkin","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2022.175070_bib5","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.parkreldis.2015.04.018","article-title":"Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis","volume":"21","author":"Bomasang-Layno","year":"2015","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib6","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1517\/14656566.2012.736490","article-title":"A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease","volume":"13","author":"Bonuccelli","year":"2012","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175070_bib55","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/mds.25961","article-title":"Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease","volume":"29","author":"Borgohain","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib56","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.parkreldis.2015.12.013","article-title":"Trajectories of recovery in depressed Parkinson\u2019s disease patients treated with paroxetine or venlafaxine","volume":"23","author":"Broen","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib59","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/mds.22948","article-title":"Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson\u2019s disease","volume":"25","author":"Bronzova","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib62","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3233\/JPD-171143","article-title":"Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease","volume":"7","author":"Cattaneo","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ejphar.2022.175070_bib63","doi-asserted-by":"crossref","unstructured":"Chaudhuri, K.R., Martinez-Martin, P., Antonini, A., B., R.G., F., J.H., Marco, O., Erwin, S., Liesbet, G., Claudia, T., 2013. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat. Disord. 19, 660-665. doi:10.1016\/j.parkreldis.2013.02.018.","DOI":"10.1016\/j.parkreldis.2013.02.018"},{"key":"10.1016\/j.ejphar.2022.175070_bib70","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1080\/14656566.2016.1202917","article-title":"Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson\u2019s disease","volume":"17","author":"Chung","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175070_bib7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175070_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/17425247.2016.1140145","article-title":"Critical appraisal of selegiline transdermal system for major depressive disorder","volume":"13","author":"Cristancho","year":"2016","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.ejphar.2022.175070_bib64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jad.2008.03.008","article-title":"Depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation","volume":"111","author":"Da Silva","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib79","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00002826-199508000-00007","article-title":"Effects of selegiline (deprenyl) on cognition in early Parkinson\u2019s disease","volume":"18","author":"Dalrymple-Alford","year":"1995","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2022.175070_bib80","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/mds.21966","article-title":"Comparison of desipramine and citalopram treatments for depression in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study","volume":"23","author":"Devos","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib9","first-page":"268","article-title":"Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: a systematic review","volume":"19","author":"Farajdokht","year":"2020","journal-title":"EXCLI. J."},{"key":"10.1016\/j.ejphar.2022.175070_bib11","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/00207450701239418","article-title":"The effects of antidepressants in Parkinson's disease: a meta-analysis","volume":"118","author":"Frisina","year":"2008","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ejphar.2022.175070_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejphar.2022.175070_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ncl.2019.12.003","article-title":"Treatment of nonmotor symptoms associated with Parkinson disease","volume":"38","author":"Goldman","year":"2020","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.ejphar.2022.175070_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000002898","article-title":"Detecting depression in Parkinson disease: a systematic review and meta-analysis","volume":"87","author":"Goodarzi","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF02229158","article-title":"A multicenter Italian randomised study on early treatment of Parkinson disease: comparison of 1-dopa, 1deprenyl and dopaminoagonists. Study design and short term results","volume":"13","author":"Group","year":"1992","journal-title":"Ital. J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2022.175070_bib61","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ana.410330404","article-title":"A controlled trial of lazabemide (RO19-6327) in untreated Parkinson\u2019s disease","volume":"33","author":"Group","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib82","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archneur.1994.00540160036006","article-title":"A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson\u2019s disease","volume":"51","author":"Group","year":"1994","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib83","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ana.410400116","article-title":"Effect of lazabemide on the progression of disability in early Parkinson\u2019s disease","volume":"40","author":"Group","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.1997.03550020057038","article-title":"Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study","volume":"278","author":"Group","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2022.175070_bib85","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","author":"Group","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib86","doi-asserted-by":"crossref","unstructured":"Guttman, M., 1997. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson\u2019s disease. Neurology 49, 1060-1065. Hauser, R.A., Silver, D., Choudhry, A., Eyal, E., Isaacson, S., investigators, A.s., 2014. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease. Mov. Disord. 29, 1028-1034. doi:10.1002\/mds.25877.","DOI":"10.1002\/mds.25877"},{"key":"10.1016\/j.ejphar.2022.175070_bib87","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/mds.25877","article-title":"Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson\u2019s disease","volume":"29","author":"Hauser","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12883-016-0610-7","article-title":"Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease","volume":"16","author":"Hauser","year":"2016","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.clineuro.2018.11.001","article-title":"Gender and onset age related-differences of non-motor symptoms and quality of life in drug-na\u00efve Parkinson's disease","volume":"175","author":"Hu","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejphar.2022.175070_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/mds.26087","article-title":"Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease","volume":"30","author":"Hu","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib19","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1037\/neu0000583","article-title":"Depressive symptoms precede cognitive impairment in de novo Parkinson's disease patients: analysis of the PPMI cohort","volume":"33","author":"Jones","year":"2019","journal-title":"Neuropsychology"},{"key":"10.1016\/j.ejphar.2022.175070_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jns.2014.10.014","article-title":"Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?","volume":"347","author":"Kataoka","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2022.175070_bib65","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S1474-4422(18)30239-4","article-title":"Apomorphine subcutaneous infusion in patients with Parkinson\u2019s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"17","author":"Katzenschlager","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejphar.2022.175070_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcms.2010.11.001","article-title":"Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias","volume":"39","author":"Knobloch","year":"2011","journal-title":"J. Cranio-Maxillo-Fac. Surg."},{"key":"10.1016\/j.ejphar.2022.175070_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0b013e31823b1da8","article-title":"Combined beneficial effect of rasagiline on motor function and depression in de novo PD","volume":"35","author":"Korchounov","year":"2012","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2022.175070_bib88","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/mds.870120207","article-title":"The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: An interim analysis of a Norwegian-Danish 5-year study","volume":"12","author":"Larsen","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib89","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1046\/j.1468-1331.1999.650539.x","article-title":"Does selegiline modify the progression of early Parkinson\u2019s disease? results from a five-year study. the Norwegian-Danish study group","volume":"6","author":"Larsen","year":"1999","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib90","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/gps.865","article-title":"SSRIs in the treatment of depression in Parkinson\u2019s disease","volume":"18","author":"Leentjens","year":"2003","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.ejphar.2022.175070_bib91","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","article-title":"Clinical evaluation of pramipexole in advanced Parkinson\u2019s disease: Results of a double-blind, placebo-controlled, parallel-group study","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib23","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ana.25581","article-title":"Depression as a risk factor for impulse control disorders in Parkinson disease","volume":"86","author":"Mar\u00edn-Lahoz","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/mds.26510","article-title":"Nonmotor features of Parkinson's disease subtypes","volume":"31","author":"Marras","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib25","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/gps.4834","article-title":"Efficacy and tolerability of antidepressants in Parkinson's disease: a systematic review and network meta-analysis","volume":"33","author":"Mills","year":"2018","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.ejphar.2022.175070_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejphar.2022.175070_bib99","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson\u2019s disease: results from a European multicenter trial","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib28","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.parkreldis.2014.02.025","article-title":"Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease","volume":"20","author":"Moonen","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40263-018-0540-6","article-title":"Assessment and management of neuropsychiatric symptoms in Parkinson's disease","volume":"32","author":"Mueller","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2022.175070_bib100","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/mds.10538","article-title":"Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor","volume":"18","author":"Navan","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jns.2017.01.066","article-title":"Effects of duloxetine on motor and mood symptoms in Parkinson's disease: an open-label clinical experience","volume":"375","author":"Nishijima","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2022.175070_bib101","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00415-014-7427-3","article-title":"Transdermal rotigotine in advanced Parkinson\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"261","author":"Nomoto","year":"2014","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib31","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1212\/01.wnl.0000338145.24512.02","article-title":"Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?","volume":"72","author":"Okun","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib71","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.parkreldis.2010.12.003","article-title":"Memantine for non-motor features of Parkinson\u2019s disease: a double-blind placebo controlled exploratory pilot trial","volume":"17","author":"Ondo","year":"2011","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib102","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib104","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson\u2019s disease: a double blind, placebo controlled, randomised, multicentre study","volume":"66","author":"Pinter","year":"1999","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2022.175070_bib105","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson\u2019s disease: a double-blind, double-dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejphar.2022.175070_bib66","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jnnp.72.6.713","article-title":"Pramipexole in patients with Parkinson\u2019s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study","volume":"72","author":"Pogarell","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejphar.2022.175070_bib32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1212\/WNL.0000000000009285","article-title":"A call for better depression treatment in people with Parkinson disease","volume":"94","author":"Pontone","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib33","first-page":"1213","article-title":"Meta-analysis of selective serotonin reuptake inhibitors (SSRIs) compared to tricyclic antidepressants (TCAs) in the efficacy and safety of anti-depression therapy in Parkinson's disease (PD) patients","volume":"13","author":"Qiu","year":"2014","journal-title":"Iran. J. Pharm. Res. (IJPR)"},{"key":"10.1016\/j.ejphar.2022.175070_bib98","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":"Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3 months\u2019 duration","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib68","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.parkreldis.2011.12.006","article-title":"Pardoprunox as adjunct therapy to levodopa in patients with Parkinson\u2019s disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial","volume":"18","author":"Rascol","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib97","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/jcph.678","article-title":"A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson\u2019s disease-associated chronic pain","volume":"56","author":"Rascol","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175070_bib96","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease: A national multicentre prospective randomized study","volume":"10","author":"Rektorov\u00e1","year":"2003","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib34","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1212\/WNL.49.4.1168","article-title":"A survey of antidepressant drug use in Parkinson\u2019s disease","volume":"49","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib35","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib95","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.parkreldis.2013.03.003","article-title":"Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson\u2019s disease -- a randomized study","volume":"19","author":"Romenets","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib36","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1080\/14656566.2019.1612877","article-title":"Drug treatment strategies for depression in Parkinson disease","volume":"20","author":"Ryan","year":"2019","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2022.175070_bib37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jns.2019.06.030","article-title":"Treatment of depression in Parkinson's disease","volume":"404","author":"Saleem","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2022.175070_bib94","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.23590","article-title":"Pardoprunox in early Parkinson\u2019s disease: results from 2 large, randomized double-blind trials","volume":"26","author":"Sampaio","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib39","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00415-019-09657-7","article-title":"Parkinson's disease multimodal complex treatment improves motor symptoms, depression and quality of life","volume":"267","author":"Scherbaum","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib60","first-page":"1010","article-title":"A Comparison Between Low Doses of Amitriptyline and Low Doses of Fluoxetin Used in the Control of Depression in Patients Suffering From Parkinson\u2019s Disease","volume":"35","author":"Serrano-Due\u00f1as","year":"2002","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib93","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ana.10191","article-title":"Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson\u2019s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial","volume":"51","author":"Shoulson","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejphar.2022.175070_bib92","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jamaneurol.2014.2472","article-title":"Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability","volume":"72","author":"Smith","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ejphar.2022.175070_bib78","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/mds.20145","article-title":"Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson\u2019s disease patients","volume":"19","author":"Stern","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2169\/internalmedicine.1359-18","article-title":"Antidepressants for depression, apathy, and gait instability in Parkinson's disease: a multicenter randomized study","volume":"58","author":"Takahashi","year":"2019","journal-title":"Intern. Med."},{"key":"10.1016\/j.ejphar.2022.175070_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10048-020-00607-4","article-title":"Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients","volume":"21","author":"Tantawy","year":"2020","journal-title":"Neurogenetics"},{"key":"10.1016\/j.ejphar.2022.175070_bib77","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/mds.23441","article-title":"Rotigotine effects on early morning motor function and sleep in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study (RECOVER)","volume":"26","author":"Trenkwalder","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2018.08.003","article-title":"Rotigotine transdermal patch for the treatment of neuropsychiatric symptoms in Parkinson's disease: a meta-analysis of randomized placebo-controlled trials","volume":"393","author":"Wang","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejphar.2022.175070_bib76","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000252355.79284.22","article-title":"Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease","volume":"68","author":"Watts","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib74","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/mds.26617","article-title":"Rasagiline for mild cognitive impairment in Parkinson\u2019s disease: A placebo-controlled trial","volume":"31","author":"Weintraub","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib75","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2022.175070_bib67","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/08039489850139049","article-title":"Depression in idiopathic Parkinson\u2019s disease treated with citalopram: A placebo-controlled trial","volume":"52","author":"Wermuth","year":"1998","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2022.175070_bib73","doi-asserted-by":"crossref","unstructured":"Werneck, A. L. S., Rosso, A.L., Vincent, M.B., 2009. The use of an antagonist 5-HT2a\/c for depression and motor function in Parkinson's sisease. Arq. Neuropsiquiatr. 67, 407-412. Sampaio, C., Bronzova, J., Hauser, R.A., Lang, A.E., Rascol, O., van de Witte, S.V., Theeuwes, A.A., Rembrandt\/Vermeer Study, G., 2011. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov. Disord. 26, 1464-1476. doi:10.1002\/mds.23590.","DOI":"10.1002\/mds.23590"},{"key":"10.1016\/j.ejphar.2022.175070_bib45","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1176\/appi.neuropsych.11090210","article-title":"Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?","volume":"24","author":"Zahodne","year":"2012","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.ejphar.2022.175070_bib72","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.parkreldis.2013.07.009","article-title":"The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson\u2019s disease: a multicenter, double-blind, randomized, placebo-controlled study","volume":"19","author":"Zhang","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ejphar.2022.175070_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006698","article-title":"Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis","volume":"96","author":"Zhuo","year":"2017","journal-title":"Medicine"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922003314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:17:44Z","timestamp":1762143464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922003314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":97,"alternative-id":["S0014299922003314"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175070","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and acceptability of drug treatments for Parkinson\u2019s disease with depression: A systematic review with network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175070"}}